Grant: Collaborative Science, Technology and Innovation Program - Collaborative R&D Initiatives
University of Ottawa
$200,000.00
Precision targeted mRNA lipid/lipid-polymer nanoparticles for modulation of the tumor microenvironment (TME)
FY 2021-22 · 2022-02-28
Summary
The tumor microenvironment (TME) is immunosuppressive and presents many challenges to cancer therapies. Modulating TME to be less immunosuppressive will block tumor immune escape and enhance the effects of cancer immunotherapies such as T-cell therapies. However, TME modulating agents need to be selectively delivered to the tumors to protect them from degradation and inducing unwanted toxicity to healthy organs. This project will develop novel nanoparticle systems containing TME modulating messenger RNA (mRNA) and selectively deliver them to tumors to modulate the TME. The team will assess the therapeutic effects of our mRNA-nanoparticle systems in clinically relevant in vitro and in vivo
models. If successful in modulating the TME to be less immunosuppressive, the proposed technologies will have tremendous potential in the advancement of future CAR-T or other types of cellular immunotherapies for solid tumours.
Department
Program
Collaborative Science, Technology and Innovation Program - Collaborative R&D Initiatives
Recipient
Location
Ottawa|Ottawa, Ontario, Canada
Recipient Type
Academia
Business Number
119278877
Type
Grant
Source
Proactive Disclosure - Grants and Contributions
Amendments
Each version of the agreement as published, oldest first, with its total as of that version. The amount above is the latest.
| Amendment | Date | Fiscal Year | Total |
|---|---|---|---|
| 0 | 2022-02-28 | 2021-22 | $200,000.00 |
| 1 | 2022-02-28 | 2021-22 | $200,000.00 |
As published
Additional Information
This agreement has been amended 1 time(s). The end date of this agreement has been modified by 364 days.
Additional Information (French)
Cet accord a été modifié 1 fois. La date de fin du présent accord a été changé de 364 jours.
Agreement End Date
2025-03-31
Agreement Number
987590
Agreement Start Date
2022-02-28
Agreement Title
Precision targeted mRNA lipid/lipid-polymer nanoparticles for modulation of the tumor microenvironment (TME)
Agreement Title (French)
Nanoparticules lipidiques et lipidiques-polymères à ARNm ciblées avec précision pour la modulation du microenvironnement tumoral
Agreement Type
Grant
Agreement Value
$200,000.00
Amendment Date
2024-02-27
Amendment Number
1
Description
The tumor microenvironment (TME) is immunosuppressive and presents many challenges to cancer therapies. Modulating TME to be less immunosuppressive will block tumor immune escape and enhance the effects of cancer immunotherapies such as T-cell therapies. However, TME modulating agents need to be selectively delivered to the tumors to protect them from degradation and inducing unwanted toxicity to healthy organs. This project will develop novel nanoparticle systems containing TME modulating messenger RNA (mRNA) and selectively deliver them to tumors to modulate the TME. The team will assess the therapeutic effects of our mRNA-nanoparticle systems in clinically relevant in vitro and in vivo
models. If successful in modulating the TME to be less immunosuppressive, the proposed technologies will have tremendous potential in the advancement of future CAR-T or other types of cellular immunotherapies for solid tumours.
Description (French)
Nanoparticules lipidiques et lipidiques-polymères à ARNm ciblées avec précision pour la modulation du microenvironnement tumoral
Expected Results
In the short term, anticipated outcomes will be strengthened collaborations across industry, academia, and government to support research excellence. In the medium term, anticipated outcomes will be the development of new and potentially disruptive technologies with collaborators. In the long term, find collaborative solutions to public policy challenges and create stronger innovation systems.
Expected Results (French)
À court terme, les résultats prévus seront des collaborations renforcées entre l'industrie, le milieu universitaire et le gouvernement pour soutenir l'excellence en recherche. À moyen terme, les résultats attendus seront le développement de nouvelles technologies potentiellement perturbatrices avec des collaborateurs. À long terme, trouver des solutions collaboratives aux défis des politiques publiques et créer des systèmes d'innovation plus solides.
Federal Riding
Ottawa–Vanier
Federal Riding (French)
Ottawa–Vanier
Federal Riding Number
35078
NAICS Code
541710 - R&D in the physical, engineering and life sciences
Organization Code
nrc-cnrc
Organization
National Research Council Canada | Conseil national de recherches Canada
Program Name
Collaborative Science, Technology and Innovation Program - Collaborative R&D Initiatives
Program Name (French)
Programme de collaboration en science, en technologie et en innovation - Initiatives de collaboration en R-D
Program Purpose
Collaborate on multiparty research and development programs to catalyze transformative, high-risk, high-reward research with the potential for game-changing scientific discoveries and technological breakthroughs in priority areas.
Program Purpose (French)
Collaborer à des programmes multipartites de recherche-développement dans le but de profiter de la synergie entre la recherche transformatrice à haut risque et à haut rendement et le potentiel de découvertes scientifiques et de percées technologiques révolutionnaires dans des secteurs d’intervention prioritaires.
Recipient Business Number
119278877
Recipient City
Ottawa|Ottawa
Recipient Country
CA
Recipient Legal Name
University of Ottawa
Recipient Postal Code
K1N 6N5
Recipient Province or Territory
ON
Recipient Type
S
Reference Number
172-2021-2022-Q4-987590
